ALS/FTD assembly modulator program
preclinicaldrug program · high · Fri May 02 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
Develop an assembly-modulating small-molecule therapeutic approach for C9orf72-associated ALS/FTD and related ALS pathology.
Small-molecule protein assembly modulation evaluated in a C9orf72 ALS/FTD mouse model, human iPSC-derived motor neurons, and peripheral blood mononuclear cell signature studies.
2025 preclinical evaluation of PAV-615 in a mouse model of C9orf72-associated ALS/FTD and related poster/publication evidence.
Supplied titles report preclinical evaluation, animal-model assessment, human iPSC-derived motor neuron assessment, and an ALS assembly modulator signature in PBMCs; detailed outcomes are not provided in the supplied material.
Alzheimer's disease oxidized MIF program
exploratorydrug program · medium
Investigate oxidized MIF as an Alzheimer's disease drug target linked to tau pathology and external risk factors.
Target-discovery and disease-mechanism research connected to Prosetta's assembly modulation approach.
2025 publication identifying oxidized MIF as an Alzheimer's disease drug target.
The supplied title states oxidized MIF is an Alzheimer's disease drug target relaying external risk factors to tau pathology; detailed results are not provided in the supplied material.
Antibacterial program
undiscloseddrug program · low
Develop antibacterial therapeutics using Prosetta's small-molecule protein assembly modulation approach.
Small-molecule modulation of multi-protein complex assembly; specific bacterial target or assay details are not provided in the supplied material.
Listed in the supplied pipeline as Antibacterial Program.
HIV program
undiscloseddrug program · low
Develop therapeutics for Human Immunodeficiency Virus using Prosetta's small-molecule protein assembly modulation approach.
Small-molecule modulation of multi-protein complex assembly; specific HIV assay or candidate details are not provided in the supplied material.
Listed in the supplied pipeline as Human Immunodeficiency Virus (HIV) and HIV Program.
Neglected viral disease program
undiscloseddrug program · low
Develop antiviral therapeutics for neglected viral diseases using Prosetta's assembly modulation approach.
Small-molecule modulation of protein assembly; specific disease target, assay, or candidate details are not provided in the supplied material.
Listed in the supplied pipeline as Neglected Viral Disease Program.
Pan-cancer oncology assembly modulator program
preclinicaldrug program · high
Develop small-molecule protein assembly modulators with selective cytotoxicity and therapeutic efficacy across cancer indications.
Small-molecule protein assembly modulation, structure-activity relationship exploration, and animal validation of pan-cancer chemical series.
2025 structure-activity relationship exploration and animal validation report for novel assembly modulator small-molecule chemical series with pan-cancer selective cytotoxicity.
Supplied titles report pan-cancer therapeutic efficacy, selective cytotoxicity, SAR exploration, and animal validation; detailed outcomes are not provided in the supplied material.
Pan-respiratory antiviral program
preclinicaldrug program · high
Develop a pan-respiratory antiviral chemotype targeting host or viral assembly processes, including SARS-CoV-2 replication.
Small-molecule viral or host multi-protein complex assembly inhibition evaluated in respiratory antiviral models and airway epithelial cells.
2024 publications describing a pan-respiratory antiviral chemotype and a viral assembly inhibitor that blocks SARS-CoV-2 replication in airway epithelial cells.
Supplied titles report targeting a transient host multi-protein complex and blocking SARS-CoV-2 replication in airway epithelial cells; detailed results are not provided in the supplied material.
Parkinson's disease program
undiscloseddrug program · low
Develop a neuroscience therapeutic program for Parkinson's disease using Prosetta's assembly modulation approach.
Small-molecule modulation of multi-protein complex assembly; specific Parkinson's target, candidate, or assay details are not provided in the supplied material.
Listed in the supplied pipeline as Parksinson's Program.
Protein assembly modulation platform
exploratoryplatform · medium
Identify and advance small molecules that modulate assembly of multi-protein complexes within cells across oncology, antiviral, respiratory, neuroscience, antibacterial, and HIV programs.
Cell-free protein synthesis and assembly-informed discovery of small-molecule protein assembly modulators.
2025 publication listed as Assembly Modulation: An Emergent Drug Discovery Strategy Revealed by Viruses and Applicable Across Therapeutic Areas.
The supplied material describes Prosetta's platform as applying protein assembly modulation to multiple therapeutic areas; detailed platform performance data are not provided.
